by Victoria Johnson
ADP-A2M4CD8 will be evaluated in the phase 2 SURPASS-3 trial initiating in late 2022 or early 2023.
ADP-A2M4CD8, a CD8+ T-cell receptor (TCR) engineered T-cell therapy has yielded responses across a variety of MAGE-A4+ solid tumors, including
… Read moreCCR scientists have identified dozens of naturally occurring receptors that direct immune cells to tumors with mutations in p53, the most commonly mutated gene in human cancers. The research team, led by Steven Rosenberg, M.D., Ph.D., Chief of the … Read more
In an interview with Targeted Oncology, Erika P. Hamilton, MD, discussed the early clinical activity seen with DS-6000a in patients with advanced ovarian cancer or renal cell carcinoma with disease progression following standard of care treatment.
Interim data from a … Read more
by Brielle Benyon
Tafinlar plus Mekinist is now approved by the Food and Drug Administration to treat adults and children over the age of 6 who have BRAF V600-mutant advanced solid cancers.
The Food and Drug Administration (FDA) approved Tafinlar
by Chris Ryan
The antibody-drug conjugate farletuzumab ecteribulin demonstrated notable antitumor activity with a manageable safety profile in patients with platinum-resistant ovarian cancer.
The antibody-drug conjugate (ADC) farletuzumab ecteribulin (MORab-202) demonstrated notable antitumor activity with a manageable safety profile in
by University of Texas M.D. Anderson Cancer Center
Newswise — CHICAGO ― Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising activity with novel immunotherapies and targeted therapies for … Read more
MEDICAL COLLEGE OF WISCONSIN
The study’s findings suggest targeting protein FXR1 to inhibit the progression of the cMYC oncogene, a gene mutation often over-expressed in patients with ovarian cancer
Scientists at the Medical College of Wisconsin (MCW) Cancer Center and … Read more
by Alison Kanski
NEW YORK – Pharma companies are racing to develop oral ATR inhibitors that present a unique pan-cancer market opportunity.
Researchers reported positive Phase I results on one of these drugs, Repare Therapeutics’ RP3500, last month across tumor … Read more
by Kelly Irvin
The number one reason to participate in a clinical trial is because someone has to do it so new drugs can be developed to treat and even cure cancer. All of the drugs we have now were … Read more
By Wistar Institute
Newswise — PHILADELPHIA — (Sept. 21, 2021) — Mutations in the ARID1A gene are present in more than 50% of ovarian clear cell carcinomas (OCCC), for which effective treatments are lacking. Scientists at The Wistar Institute discovered … Read more
Results from the phase II MyPathway basket trial found that the HER2-targeted therapies pertuzumab and trastuzumab demonstrated durable activity in patients with a wide variety of tumors marked by HER2 amplification or overexpression, although responses were limited in those with … Read more
An independent data safety monitoring committee has not observed any safety issues with the phase 3 OVAL trial examining VB-111 in patients with platinum-resistant ovarian cancer, and as such, has recommended that the trial continue as planned.
By Courtney Marabella… Read more
Mayo Clinic researchers have developed a novel proton therapy technique to more specifically target cancer cells that resist other forms of treatment. The technique is called LEAP, an acronym for “biologically enhanced particle therapy.” The findings are published today in … Read more
Loss of ARID1A causes increased glutamine metabolism, which can be blocked pharmacologically to target ARID1A-mutant tumors.
Mutations that inactivate the ARID1A gene in ovarian cancer increase utilization of the glutamine amino acid making cancer cells dependent on glutamine metabolism, according … Read more
One patient had a complete response and the majority of patients achieved disease control at 12 weeks.
A phase 1 trial of an anti-folate receptor alpha (FolRα) human immunoglobulin G1 (IgG1) antibody for women with advanced ovarian cancer showed responses
KSQ Therapeutics is hoping to provide hope for ovarian and breast cancer patients that have developed a resistance to drugs and those who don’t respond at all by developing a drug that may be able to boost the effectiveness of … Read more
A recent finding by researchers at UBC’s faculty of medicine and the BC Cancer Research Institute (BCCRI) may offer a new treatment possibility for people diagnosed with a rare and aggressive form of ovarian cancer.
Small cell carcinoma of the … Read more
By Clayton Boldt, Ph.D
Advanced ovarian cancer most commonly metastasizes to the omentum, a layer of fatty tissue that wraps around and protects internal organs in the abdomen, but the reasons for this have not been well-understood. In a new … Read more
By Kristin Jenkins
The presence of a BRCA germ line mutation in patients with invasive epithelial ovarian cancer may confer a short-term survival advantage, but is not associated with a reduction in long-term mortality, researchers found.
A follow-up study comparing … Read more
By Andrea S. Blevins Primeau, PhD, MBA
There are many different types of agents used in the treatment of cancer, and they can generally be classified according to molecule type or their basic mechanism of action. Different cancer types have … Read more
